OncLive TV

William B. Pearse, MD, discusses unanswered questions regarding the sequencing of pirtobrutinib and other BTK inhibitors in mantle cell lymphoma.

Callie Coombs, MD, discusses the investigation of notable BTK inhibitor combination trials in patients with chronic lymphocytic leukemia.

David Samuel Dicapua Siegel, MD, discusses a trial of carfilzomib, iberdomide, and dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

Joseph Mikhael, MD, discusses the utility of isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

Karamjeet Singh Sandhu, MD, discusses outcomes from a pooled analysis of the FELIX study in relapsed/refractory B-cell acute lymphoblastic leukemia.

Ricardo D. Parrondo, MD, discusses the exploration of the non-BCMA CAR T-cell target GPRC5D in multiple myeloma.

Talha Badar, MBBS, MD, discusses key efficacy data with imetelstat from the phase 2/3 IMerge trial of patients with lower-risk myelodysplastic syndrome.

Jane L. Meisel, MD, discusses the rationale for evaluating communication challenges that currently exist between patients and their oncologists.

Tian Zhang, MD, MHS, discusses using the adjuvant KEYNOTE-564 regimen to treat high-risk patients with renal cell carcinoma.

Jun Gong, MD, discusses the current treatment armamentarium for patients with metastatic hormone-sensitive prostate cancer.

Coral Olazagasti, MD, discusses her participation in a case-based discussion at the 21st Annual Winter Lung Cancer Conference®.

Samuel Rosner, MD, discusses ongoing efforts to individualize the use of perioperative/neoadjuvant therapy in early-stage NSCLC.

Gabriella Smith, MD, discussed the predictive value of CA-125 KELIM score for survival outcomes with HIPEC during surgery in epithelial ovarian cancer.

Joseph Mikhael, MD, discusses the importance of researching disparities in treatment outcomes for patients with multiple myeloma.

Akriti Jain, MD, discusses the outcomes of the phase 3 COMMANDS trial in transfusion-dependent lower-risk myelodysplastic syndromes.

Bradley McGregor, MD, discusses the next steps for investigating cabozantinib plus atezolizumab in patients with advanced renal cell carcinoma.

Sarah Sammons, MD, discusses the real-world incidence of brain metastases in HER2-positive breast cancer per line of treatment as well as cumulatively.

Joseph Mikhael, MD, discusses the importance of closing gaps in care for patients with multiple myeloma in underserved populations.

Balazs Halmos, MD, discusses treatment strategies for patients with EGFR-mutant non–small cell lung cancer.

David Samuel Dicapua Siegel, MD, discusses the importance of closing the gaps in cancer care and spreading awareness of current treatment inequities in oncology through campaigns such as World Cancer Day.

Wally Curran, MD, discusses current and developing treatment strategies for patients with stage III unresectable non–small cell lung cancer.

George Simon, MD, FACP, FCCP, discusses the importance of enrolling diverse patient populations in cancer clinical trials.

Benjamin Levy, MD, discusses the mechanism of action of antibody-drug conjugates in patients with non–small cell lung cancer.

Ticiana Leal, MD, discusses the variety of DLL3-targeted agents in development for patients with small cell lung cancer and neuroendocrine tumors.

Bruna Pellini, MD, discusses the importance of developing circulating tumor DNA assays with increased sensitivity.

Estelamari Rodriguez, MD, MPH, discusses adverse effects associated with HER2-directed antibody-drug conjugates in non–small cell lung cancer.

Daniel J. George, MD, discusses the phase 3b CheckMate 8Y8 study of nivolumab plus ipilimumab vs nivolumab alone in previously untreated advanced RCC

Jorge J. Castillo, MD, discusses preliminary data from a phase 2 study of acalabrutinib plus rituximab in patients with IgM symptomatic anti-MAG peripheral neuropathy.

James Yu, MD, discusses the validation of the ARCAD nomogram in the real-world setting for patients with stage IV colorectal cancer.

John Michael Bryant, MD, discusses the effects of germline DNA repair mutations on radiosensitivity in patients with pancreatic ductal adenocarcinoma.